size : | Price | Quantity | |
---|---|---|---|
5 mg | $60.00 | ||
25 mg | $240.00 |
XIB4035 (10023-54-8) is a novel small molecule thought to be an agonist at the glial cell line-derived neurotrophic factor (GDNF) family receptor GFRα-1. It inhibits radiolabeled GDNF binding in Neuro-2A cells in a concentration dependent manner IC50 = 10.4 μM. Like GDNF, XIB4035 induced Ret autophosphorylation and promoted neurite outgrowth in Neuro-2A cells.1 Recent studies indicate that it enhances GFRα family receptor signaling in conjunction with ligand stimulation. Effective treatment for small-fiber neuropathy in mouse models of the disease.2,3 GDNF agonists may be a new class of Parkinson’s disease therapeutics.4
References/Citations:
1) Tokugawa et al. (2003), XIB4035, a novel nonpeptidyl small molecule agonist for GFRα-1; Neurochem. Int., 42 81
2) Hedstrom et al. (2014), Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRα/RET receptor signaling; Proc. Natl. Acad. Sci. USA, 111 2325
3) Hsieh et al. (2018) Distinct TrkA and Ret modulated negative and positive neuropathic behaviors in a mouse model of resiniferatoxin-induced small fiber neuropathy; Exp. Neurol. 300 87
4) Drinkut et al. (2016) Ret is essential to mediate GDNF’s neuroprotective and neuroregenerative effect in Parkinson disease mouse model; Cell Death Dis., 7 e2359
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
XIB4035 (10023-54-8) is a novel small molecule thought to be an agonist at the glial cell line-derived neurotrophic factor (GDNF) family receptor GFRα-1. It inhibits radiolabeled GDNF binding in Neuro-2A cells in a concentration dependent manner IC50 = 10.4 μM. Like GDNF, XIB4035 induced Ret autophosphorylation and promoted neurite outgrowth in Neuro-2A cells.1 Recent studies indicate that it enhances GFRα family receptor signaling in conjunction with ligand stimulation. Effective treatment for small-fiber neuropathy in mouse models of the disease.2,3 GDNF agonists may be a new class of Parkinson’s disease therapeutics.4
References/Citations:
1) Tokugawa et al. (2003), XIB4035, a novel nonpeptidyl small molecule agonist for GFRα-1; Neurochem. Int., 42 81
2) Hedstrom et al. (2014), Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRα/RET receptor signaling; Proc. Natl. Acad. Sci. USA, 111 2325
3) Hsieh et al. (2018) Distinct TrkA and Ret modulated negative and positive neuropathic behaviors in a mouse model of resiniferatoxin-induced small fiber neuropathy; Exp. Neurol. 300 87
4) Drinkut et al. (2016) Ret is essential to mediate GDNF’s neuroprotective and neuroregenerative effect in Parkinson disease mouse model; Cell Death Dis., 7 e2359
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.